Curespec

Company Overview

Snapshot

Founded in December 2020 by Avner Spector, Curespec operates with 1–10 employees. The company has raised $7.4 million across two funding rounds. In March 2026, research was published on the feasibility and safety of its electrohydraulic acoustic therapy for hypertension in chronic kidney disease patients.

Business overview

Curespec is a medical device company developing noninvasive shockwave therapy for the treatment of hypertension and chronic kidney disease (CKD). Its core product, Nephrospec, is a low-intensity electro-hydraulic acoustic therapy (eHAT) device designed to generate new blood vessels and restore function to damaged tissue, aiming to improve kidney function and delay dialysis. The company serves the healthcare market, targeting providers and patients in the Health Tech & Life Sciences sector, with a focus on medical devices and treatment therapeutics.

Strategic signal

In March 2026, a study published in Frontiers in Medical Technology highlighted the feasibility and safety of Curespec's electrohydraulic acoustic therapy for hypertension in chronic kidney disease patients. This publication provides significant clinical validation for the company's core technology, signaling to investors and the medical community the potential for a new non-invasive treatment modality in a critical and underserved patient population.

Company Intelligence Q&A

What is Curespec's primary medical device?

Curespec's primary medical device is Nephrospec, a safe, low-intensity, noninvasive shockwave device that delivers electro-hydraulic acoustic therapy (eHAT) for the treatment of hypertension and chronic kidney disease (CKD).

When was Curespec founded?

Curespec was founded in December 2020 by Avner Spector.

What is the total capital raised by Curespec?

Curespec has raised a total of $7.4 million across two funding rounds.

What regulatory approvals has Curespec received?

Curespec has obtained CE approval in Europe and AMAR approval in Israel for its medical device solutions.

What was a recent significant development for Curespec?

In March 2026, research was published in Frontiers in Medical Technology on the feasibility and safety of Curespec's electrohydraulic acoustic therapy for treating hypertension in patients with chronic kidney disease.